Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01248013 · ClinicalTrials.gov registry record · NA
Irritable Bowel Syndrome Hypnotherapy
A NA study of Irritable Bowel Syndrome, sponsored by Mind-Body Digestive Center.
- Completed
- Registry status
- NA
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT01248013: Completed NA study of Irritable Bowel Syndrome, sponsored by Mind-Body Digestive Center.
NCT01248013 is a NA study of Irritable Bowel Syndrome that has completed, run by Mind-Body Digestive Center. The registered enrollment target is 89 participants, below the 142-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01248013, a NA study of Irritable Bowel Syndrome, has completed, sponsored by Mind-Body Digestive Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of the study was whether gut focused hypnotherapy, in a group format, was successful in reduction of symptoms in patients with irritable bowel syndrome. The secondary goal was to see if any outcome predictors could be determined.
Primary Outcome
assessed by symptom severity scale given before treatment began and after 7 bi-weekly sessions, at 3 months, 6 months and 12 months
Conditions Studied
Interventions
- BEHAVIORAL gut focused hypnotherapy
Study Locations (1)
New York
- Mind Body Digestive Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-12 |
| Phase | NA |
What the finished NCT01248013 record still lists
NCT01248013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 142-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which gut focused hypnotherapy is the first listed.
NCT01248013 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01248013 about?
NCT01248013 is a clinical study titled "Irritable Bowel Syndrome Hypnotherapy". The primary goal of the study was whether gut focused hypnotherapy, in a group format, was successful in reduction of symptoms in patients with irritable bowel syndrome. The secondary goal was to see if any outcome predictors could be determined.
What is the current status of trial NCT01248013?
This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2005-09. Estimated completion is 2009-12.
What conditions does trial NCT01248013 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
What interventions are being tested in trial NCT01248013?
The interventions under investigation include: gut focused hypnotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT01248013?
This trial is sponsored by Mind-Body Digestive Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01248013 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01248013's enrollment target sits among peer trials
89 24th of 47 higher than 24 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
RECRUITING · NA
-
GI Alpha-Gal Study
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
-
IBS Skin Patch Test Food Allergy Study
RECRUITING · NA
-
Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome
RECRUITING · NA
-
Well-being in IBS: Strengths and Happiness (WISH) 2.0
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia